



























































L.M. Fisk, A.J. Le Compte, G.M. Shaw, S. Penning, T. Desaive, J.G. Chase 
Pilot Trial of STAR in Medical ICU 
INTRODUCTION 
 
Background: Accurate glycemic control (AGC) has proven 
difficult without excessive hypoglycemia risk. Stochastic 
TARgeted (STAR) glycemic control forecasts changes in 
insulin sensitivity to calculate a range of glycemic outcomes 
for an insulin intervention using the ICING model pictured 
below, creating a risk framework to increase safety and 
performance. 
  
Objective: Evaluate the performance, safety and clinical 
applicability of STAR, as observed during pilot trials in 







Number of Patients 13 10 3 
Hours of control 2269 1879 389 
Patient median insulin sensitivity [Min - Max]: [0.86 – 22.4] [0.86 – 22.4] [0.91 – 2.85] 
Workload 
# BG measurements: 1258 1038 220 
Measures/day: 13.3 13.3 13.6 
Control performance 
BG median [IQR] (mmol/L): 112 [101 – 132] 109 [100 – 122] 144 [131 – 164] 
% BG within target band 85.6 88.5 71.5 
% BG > 180 mg/dL 3.86 2.54 10.3 
Safety 
% BG < 72 mg/dL 2.02 2.44 0.0 
% BG < 72 mg/dL 1.18 1.43 0.0 
% BG < 40 mg/dL 0.0 0.0 0.0 
# patients < 40 mg/dL 0 0 0 
Clinical interventions 
Median insulin rate [IQR] (U/hr): 2.5 [1.0 – 4.5] 3.0 [1.5 – 4.5] 2.0 [1.0 – 3.0] 
Median [IQR] per-patient glucose rate (g/hr): 5.4 [2.5 – 8.1] 5.5 [2.5 – 8.1] 4.8 [2.9 – 10.2] 
Table 1: Summary table of 
results from the clinical trial. 
Clinicians chose a raised 
target for 3 patients due to 
suspected diabetes. STAR 
showed a promising ability to 
target different glycemic 
ranges without dramatic 
increases in workload. 
 
Overall, the results show high 
control performance and low 
clinical effort, with safety 
preserved and no patients 
experiencing episodes of 
severe hyperglycemia despite 
a wide range of  metabolic 
conditions (wide range of 
median insulin sensitivities). 
CONCLUSIONS 
 
STAR was able to provide AGC in a clinical setting, with tight and accurate 
control extended to patients with a range of metabolic requirements. The risk-
management approach proved capable of balancing clinical workload and 
risks presented by patient variability. 
METHODS 
 
N = 13 hyperglycemic patients (blood glucose > 145mg/dL) were consented from 
Christchurch Hospital Medical ICU to participate in the pilot trial. Tablet PCs 
loaded with the STAR algorithm were placed at each beside, and were consulted 
by nursing staff after each blood glucose (BG) glucometer reading was taken. 
Measurement frequency was nurse-managed within a range of 1-3 hours, with 2 
and 3 hour measures only offered if excessive risk of either hyper- or hypo- 
glycemia was not forecasted. 
 
Enteral nutrition between 30-100% ACCP goal, and held constant when called 
for by dieticians. IV insulin boluses were delivered each hour, with doses ranging 
from 0-6 U and maximum increase between interventions limited to +2U to 
prevent over-responding to changes in BG. Insulin infusions (1-3 U/hr) were 
used in addition for patients with consistently high insulin requirements ( ≥ 5U/hr 
for 5 hours) .  
 
BG target choices were clinically made, with 80-145 mg/dL for the majority and a 
raised target chosen for poorly controlled diabetics and other exceptional cases.  
Figure 3: High dose steroids (daily doses of 1g methyl 
prednisone) were administered until approximately T=100 hrs. 
Initially, insulin sensitivity was consistently low, then rose 
significantly after weaning off steroid doses. STAR was able to 
respond safely and tailor insulin dosage to the changing 
requirement. 
Figure 2: A demonstration of the need for a dynamic response to 
changes in patient condition. Despite relatively stable BG, insulin 
sensitivity was relatively low, requiring high doses of insulin, 
supplemented by background infusions. By responding to 
increased sensitivity and backing off insulin doses STAR was 
able to maintain BG within the middle of the range despite a six-
fold increase in sensitivity over a 20hr period. 
RESULTS 
 
Median BG was 109 mg/dL for N=10 80-145 mg/dL target patients 
and 145 mg/dL for N=3 108-162 mg/dL target patients.  
 
In total, 85.6% of time was in the specified target band, with 1.18% 
of BG<72mg/dL and 2.41% BG<80mg/dL. BG measurement 
frequency was 13.3 measures/day, with a slight increase to 13.6 
measures/day for the raised target. Per-patient median 
carbohydrate intake was 5.4g/hr [IQR: 2.5-8.1g/hr] and median 
insulin usage was 2.5U/hr [IQR: 1.0-4.5 U/hr]. 
 
These results were achieved across a range of patient types from 
a medical ICU. Observed response to insulin (quantified as median 
insulin sensitivity) varied by a factor of 26x between patients. This 
wide variance indicates accurate control was maintained over a 
range of metabolic conditions, implying STAR was able to adapt 
safely. During periods on STAR dramatic changes in condition 
were observed (Figure 2), patients were given high-dose steroids 
known to inhibit insulin action (Figure 3), as well as the long-acting 
insulin analogue Glargine. 
Figure 1: A schematic of stochastic 
forecasting, as applied to glycemic control in 
STAR. A stochastic model is used to 
forecast changes in SI, based on the current 
value. This range of SI outcomes is used to 
generate BG outcomes, with A,B,C 
depicting the 5th percentile BG outcomes, 
and D,E,F depicting the 95th percentile BG 
outcomes. Treatments are chosen by 
comparing the different BG outcome ranges. 
BG outcomes typically have the distribution 
pictured. 
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